Accent Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of small-molecule precision cancer therapies that target critical intracellular dependencies spanning multiple types of cancer. Its pipeline is led by ATX-295, a novel KIF18A inhibitor in clinical development, with data presented at AACR and ASCO. - View it on GitHub